Structure Therapeutics announced Phase 2 data showing its oral GLP‑1 candidate aleniglipron produced roughly 16% placebo‑adjusted weight loss at 44 weeks. The company reported durable efficacy across dose cohorts and a tolerability strategy that reduced discontinuations, positioning the pill as an oral competitor to injectable GLP‑1 medicines. Investigators and analysts flagged the result as “best‑in‑class” for an oral GLP‑1, and Structure said it will move the program into Phase 3 later this year. The trial design used a step‑up dosing schedule to manage side effects; safety signals and dropout rates will shape regulatory dialogue as oral GLP‑1s proliferate. Sponsors, regulators and payors will watch whether an oral regimen can replicate the real‑world uptake and payer dynamics seen with injectable GLP‑1s.